Amended and restated licence agreement with Recordati and commercial launch of Fortacin™ in Europe by Recordati
Notice of Board Meeting for unaudited interim results for the six months ended 30 June 2017
Update on commercial negotiations with Recordati and commercial launch of Fortacin™ in Continental Europe
Next Day Disclosure Return (Equity issuer – changes in issued share capital and/or share buybacks)
Completion of placing of existing shares and top-up subscription of new shares under the general mandate
Placing of existing shares and top-up subscription of new shares under the general mandate
Notice of Board Meeting for audited final results for the year ended 31 December 2016